FoRx Therapeutics is a clinical‑stage biotech developing precision small‑molecule inhibitors that target DNA replication stress and DNA damage response pathways in treatment‑resistant cancers. Its lead program, FORX‑428, is a highly selective PARG inhibitor currently in Phase 1 trials, with additional replication‑stress‑modulating candidates advancing through lead optimization. The company leverages structure‑based design, biomarker‑driven patient selection, and oral‑bioavailable chemistry to deliver next‑generation anticancer therapeutics.
Funding
$10.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
4OMVFounders
Product
Problem
Many treatment‑resistant cancers rely on DNA replication stress and the associated DNA damage response (DDR) pathways to survive, yet existing therapies do not specifically target these mechanisms, leading to limited efficacy and rapid resistance.
Solution
FoRx Therapeutics develops precision small‑molecule inhibitors that exploit DNA replication stress vulnerabilities in cancer cells. By targeting key DDR enzymes such as poly (ADP‑ribose) glycohydrolase (PARG), the company aims to induce lethal DNA damage selectively in tumor cells while sparing normal tissue. Their lead candidate, FORX‑428, is a highly potent and selective PARG inhibitor currently in a Phase 1 clinical trial for patients with refractory malignancies. Additional programs (FORX‑002, FORX‑003) are advancing through lead optimization and identification to broaden the portfolio of replication‑stress‑targeted agents. The approach integrates structure‑based drug design, preclinical efficacy models, and biomarker‑driven clinical development to deliver next‑generation anticancer therapeutics.
Target Audience
Primary customers are oncology pharmaceutical companies and clinical research organizations seeking novel DDR‑targeted agents, as well as academic and biotech partners interested in co‑development of replication‑stress therapeutics for treatment‑resistant cancers.
Features
- Potent, selective inhibition of PARG, a next‑generation DDR target implicated in PARP‑inhibitor‑resistant cancers.
- Small‑molecule chemistry platform optimized for oral bioavailability and tumor penetration.
- Preclinical validation showing strong anti‑tumor activity across multiple replication‑stress‑driven cancer models.
- Clinical‑stage development pipeline including two additional replication‑stress modulators (FORX‑002, FORX‑003) in lead optimization/identification.
- Biomarker‑focused strategy to identify patients with high oncogene‑induced replication stress for targeted therapy.
- Integrated translational program linking preclinical pharmacology, pharmacokinetics, and early‑phase clinical trial design.